Abstract
The objective of this study was to identify predictors for remission or low disease activity (LDA) in established rheumatoid arthritis (RA) at 12 months of anti-TNF-α therapy. We have performed a prospective observational study in 90 consecutive patients with active RA receiving TNF-α inhibitors. Baseline and standard assessments were done every 3 months, including individual parameters (clinical and biological) and composite activity scores (28-joint disease activity score, DAS28). The primary outcome measure was DAS28-based EULAR response criteria. The multivariate logistic regression was used to analyze the association between disease activity and several RA baseline characteristics. Of the RA, 78.8 % was classified as good responders based on the EULAR-DAS28 criteria, 44.4 % RA achieving remission (DAS28 ≤ 2.6) and 34.4 %, LDA (DAS28 ≤ 3.2). Parameters associated with an increased likelihood of remission and LDA were initial DAS28-erythrocyte sedimentation rate ≤7 (odds ratio (OR) 3.3, 95 % confidence interval (CI) 2.03–5.81; OR 1.8, 95 % CI 1.09–6.68), Health Assessment Questionnaire Disability Index ≤ 2 (OR 7.0, 95 % CI 1.56–31.91; OR 1.3, 95 % CI 1.03–5.79), C-reactive protein level ≤20 mg/l (OR 1.5, 95 % CI 0.29–8.22; OR 0.5, 95 % CI0.08–2.97), rheumatoid factor ≤20 IU/ml (OR 18.9, 95 % CI 10.79–38.36; OR 32.9, 95 % CI 4.03–269), anti-cyclic citrullinated peptide antibodies ≤40 IU/ml (OR 3.5, 95 % CI 0.67–18.19; OR 1.2, 95 % CI 1.02–1.59), concurrent prednisolone (OR 0.2, 95 % CI 0.05–0.36; OR 0.2, 95 % CI 0.06–0.63), methotrexate or leflunomide (OR 1.6, 95 % CI 1.2–13.53; OR 2.9, 95 % CI 1.20–4.36). A predictive matrix for remission and LDA in established active RA patients receiving TNF-α inhibitors was proposed. Further studies are necessary to confirm the value of such matrix in particular RA settings, leading to optimization of the use of anti-TNF-α therapy.
Similar content being viewed by others
References
Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, Fokke C, Goodson N, Jeffreson P, Lamb E, Mohammed R, Oliver S, Stableford Z, Walsh D, Washbrook C, Webb F, British Society for Rheumatology, British Health Professionals in Rheumatology Standards Guidelines and Audit Working Group (2006) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 45:1167–1169
Bykerk V, Keystone E (2005) What are the goals and principles of management in the early treatment of rheumatoid arthritis. Best Pract Res ClinRheumatol 19:147–161
Fransen J, Moens HB, Speyer I, van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomized controlled trial. Ann Rheum Dis 64:1294–1298
Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (camera, an open-label strategy trial). Ann Rheum Dis 66:1443–1449
Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F et al (2011) Group for respect of ethics and excellence in science (grees). Biomarkers and personalized medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 70(10):1713–1718
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:1–229, iii–iv, xi–xiii
Marotte H, Miossec P (2010) Biomarkers for prediction of TNFα blockers response in rheumatoid arthritis. Joint Bone Spine 77:297–05
Mader R, Keystone E (2007) Optimizing treatment with biologics. J Rheumatol Suppl 80:16–24
Erickson AR, Mikuls TR (2007) Switching anti–TNF-alpha agents: what is the evidence. CurrRheumatol Rep 9(5):416–420
Bolosiu H, Ionescu R, Chirieac R, Georgescu L, Rednic S, Suta M, et al. (2011) Ghidul de tratament al poliartriteireumatoide. RevistaRomană de Reumatologie vol. xx nr. 1; 36–53.
van Gestel AM, Prevoo ML, van Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39:34–40
Katchamart W, Johnson S, Lin H, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62:1128–1143
Vazquez I, Graell E, Gratacos J, Canete JD, Vinas O, Ercilla MG et al (2007) Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. ClinExpRheumatol 25:231–238
Forslind K, Hafstrom I, Ahlmen M, Svensson B (2007) The BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis. Ann Rheum Dis 66:46–52
Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59:32–41
Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish arthritis treatment group register. Rheumatology (Oxford) 47:495–499
Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC et al (2005) A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 64:38–43
Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D et al (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: the GISEA study. J Rheumatol 34:1670–1673
Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J (2002) For the FIN-RACo Trial Group. Delay to institution of therapy and induction of remission using singledrug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898
Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558–1565
Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P (2007) For the TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928–3939
Molenaar ET, Voskuyl AE, van der Horst-Bruinsma IE, Schreuder GM, Zanelli E, Dijkmans BA (2002) Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 61:351–353
Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register (2006) Comparison of the response to infliximab or etanerceptmonotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:1786–1794
Liang GC, Cordero M, Dyer A, Chang RW (2005) Current tumor necrosis factor-α inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 32:1662–1665
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pomirleanu, C., Ancuta, C., Miu, S. et al. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. Clin Rheumatol 32, 665–670 (2013). https://doi.org/10.1007/s10067-012-2146-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2146-6